Skip to content
DataLookout
Menu

NCT01703949

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 37 versions: 27 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria shortened, about 17 words
    • Study completion moved earlier from Jun 3, 2030 to Aug 16, 2028
    • Site details revised
  2. Notable Results first posted: May 12, 2026
    • Primary endpoint revised
    v36
  3. Minor Primary completion date changed from estimate of Apr 21, 2025 to Jun 3, 2025
    • Study completion date: Apr 21, 2030 to Jun 3, 2030
    v35
  4. Minor Trial status: Recruiting to Active, Not Recruitingv34 Show 4 more changesShow less
    • Enrollment target: estimated 40 to confirmed 28
    • Primary completion date: Mar 1, 2025 to Apr 21, 2025
    • Study completion date: Mar 1, 2026 to Apr 21, 2030
    • Site details revised
  5. Notable Primary completion date: Sep 1, 2024 to Mar 1, 2025
    • Study completion date: Sep 1, 2025 to Mar 1, 2026
    v32
Show 21 earlier versionsHide 21 earlier versions
  1. Notable Eligibility criteria expanded, about 11 wordsv29
  2. Notable Primary completion date: Jan 15, 2024 to Sep 1, 2024
    • Study completion date: Jan 15, 2024 to Sep 1, 2025
    v27
  3. Notable Eligibility criteria expanded, about 16 wordsv26
  4. Notable Primary and study completion dates: Jan 15, 2023 to Jan 15, 2024v25
  5. Minor Collaborators shortened, about 4 wordsv24
  6. Notable Primary and study completion dates: Jan 15, 2022 to Jan 15, 2023
    • Study description shortened, about 192 words
    • Site contact updated
    v22
  7. Notable Primary and study completion dates: Jan 15, 2021 to Jan 15, 2022v21
  8. Minor Study completion date: Jan 15, 2021v20
  9. Minor Eligibility criteria revised
    • Site contact updated
    • Study description shortened, about 2 words
    v18
  10. Notable Phase: Not applicable to Phase 2v17 Show 8 more changesShow less
    • Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 8 to 40
    • Eligibility criteria expanded, about 170 words
    • Interventions: Brentuximab Vedotin (Drug), Laboratory Biomarker Analysis (Other) to Brentuximab Vedotin (Drug), Laboratory Biomarker Analysis (Other), Nivolumab (Biological)
    • Study description expanded, about 98 words
    • Site details revised
    • Study arms: 1 to 2
    • Study title expanded, about 4 words
  11. Notable Primary completion date: Jun 2015 to Jan 15, 2021
    • Start date: Mar 2013 to Mar 20, 2013
    v15
  12. Minor Interventions: brentuximab vedotin (Drug), laboratory biomarker analysis (Other) to Brentuximab Vedotin (Drug), Laboratory Biomarker Analysis (Other)
    • Study site revised
    • Study description expanded, about 1 word
    v14
  13. Minor Primary completion date changed from estimate of Dec 2016 to Jun 2015v13
  14. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 8
    • Site details revised
    v12
  15. Minor Primary completion date: Jun 2016 to Dec 2016v11
  16. Notable Primary completion date: Jun 2015 to Jun 2016v10
  17. Minor Primary completion date: Mar 2015 to Jun 2015v9
  18. Study Identification, Study Status, Study Description, Arms and Interventionsv6
  19. Notable Lead sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium to University of Washingtonv5
  20. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 2013 to Mar 2013
    • Site details revised
    v3
  21. Notable Start date: Oct 2012 to Apr 2013v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Response Rate as Measured by the Cheson 2007 Criteria
Timeframe: For Arm A: Up to 5 weeks after completion of study treatment (an average of 1 month). For Arm B: within 6 months following treatment (an average of 1 month).

Arms and interventions

Arm A (brentuximab vedotin)Experimental

Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

Arm B (brentuximab vedotin, nivolumab)Experimental

Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

Drugs: Brentuximab Vedotin

Other: Laboratory Biomarker Analysis

Biologicals: Nivolumab

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States